<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39443721</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1740-634X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>23</Day></PubDate></JournalIssue><Title>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</Title><ISOAbbreviation>Neuropsychopharmacology</ISOAbbreviation></Journal><ArticleTitle>Extended course accelerated intermittent theta burst stimulation as a substitute for depressed patients needing electroconvulsive therapy.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41386-024-02007-w</ELocationID><Abstract><AbstractText>In response to restrictions on electroconvulsive therapy (ECT) access during COVID-19, we designed a trial to assess the clinical outcomes service impacts, employing an extended course of accelerated intermittent theta burst stimulation (aiTBS), in patients with moderate to severe depression in need of ECT. This open label clinical trial was comprised of 3 phases: (i) an acute phase, where iTBS treatments were administered 8 times daily, for up to 10 days; (ii) a tapering phase of 2 treatment days per week for 2 weeks, followed by 1 treatment day per week for 2 weeks; and (iii) a symptom-based relapse prevention phase, whereby treatments were scheduled based on symptom re-emergence, for up to 6 months. Of the 155 patients who completed the acute phase of the study, the remission rate was 16.1%. The mean reduction from baseline on the HRSD-24 was 29.4% (p &lt; 0.001) and the response rate was 25.2%. Of the 110 patients who completed the tapering phase, the mean reduction from baseline was 42.6% (p &lt; 0.001) and response and remission rates were 49.6% and 34.8%, respectively. Of the 61 patients who were eligible for the relapse prevention phase, 43 completed, with a mean reduction from baseline of 60.1% (p &lt; 0.001); 7 patients relapsed during this phase. This study demonstrated that an extended aiTBS protocol safely led to meaningful clinical outcomes in patients with severe depression, who otherwise would have received ECT, and thus reduced pressure on ECT services during the pandemic. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04384965 ( https://clinicaltrials.gov/study/NCT04384965?term=NCT04384965&amp;rank=1 ).</AbstractText><CopyrightInformation>© 2024. The Author(s), under exclusive licence to American College of Neuropsychopharmacology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goodman</LastName><ForeName>Michelle S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trevizol</LastName><ForeName>Alisson P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konstantinou</LastName><ForeName>Gerasimos N</ForeName><Initials>GN</Initials><Identifier Source="ORCID">0000-0002-0303-1633</Identifier><AffiliationInfo><Affiliation>Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boivin-Lafleur</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Laval University, Quebec City, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brender</LastName><ForeName>Ram</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Royal Ottawa Mental Health Centre and Department of Psychiatry, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Downar</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaster</LastName><ForeName>Tyler S</ForeName><Initials>TS</Initials><Identifier Source="ORCID">0000-0002-5299-4794</Identifier><AffiliationInfo><Affiliation>Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knyahnytska</LastName><ForeName>Yuliya</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Queen's University, Kingston, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vila-Rodriguez</LastName><ForeName>Fidel</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Non-Invasive Neurostimulation Therapies Laboratory, Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Biomedical Engineering, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voineskos</LastName><ForeName>Daphne</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Poul Hansen Family Centre for Depression, University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daskalakis</LastName><ForeName>Zafiris J</ForeName><Initials>ZJ</Initials><AffiliationInfo><Affiliation>University of California San Diego, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blumberger</LastName><ForeName>Daniel M</ForeName><Initials>DM</Initials><Identifier Source="ORCID">0000-0002-8422-5818</Identifier><AffiliationInfo><Affiliation>Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, ON, Canada. daniel.blumberger@camh.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Toronto, ON, Canada. daniel.blumberger@camh.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04384965</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Neuropsychopharmacology</MedlineTA><NlmUniqueID>8904907</NlmUniqueID><ISSNLinking>0893-133X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>16</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>16</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39443721</ArticleId><ArticleId IdType="doi">10.1038/s41386-024-02007-w</ArticleId><ArticleId IdType="pii">10.1038/s41386-024-02007-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Spaans HP, Verwijk E, Comijs HC, Kok RM, Sienaert P, Bouckaert F, et al. Efficacy and cognitive side effects after brief pulse and ultrabrief pulse right unilateral electroconvulsive therapy for major depression: a randomized, double-blind, controlled study. J Clin Psychiatry. 2013;74:e1029–36. https://doi.org/10.4088/JCP.13m08538 .</Citation><ArticleIdList><ArticleId IdType="doi">10.4088/JCP.13m08538</ArticleId><ArticleId IdType="pubmed">24330903</ArticleId></ArticleIdList></Reference><Reference><Citation>Angus H, Williams D, Anderson M Memorandum to Ontario Health and hospitals. Ramping down elective surgeries and other non-emergent activities. Toronto: Ministry of Health; 2020.</Citation></Reference><Reference><Citation>Williams DC Directive #2 for health care providers (regulated health professionals or persons who operate a group practice of regulated health professionals) 2020.</Citation></Reference><Reference><Citation>Fink M, Kellner CH, McCall WV. The role of ECT in suicide prevention. J ECT. 2014;30:5–9. https://doi.org/10.1097/YCT.0b013e3182a6ad0d .</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/YCT.0b013e3182a6ad0d</ArticleId><ArticleId IdType="pubmed">24091903</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaster TS, Blumberger DM, Gomes T, Sutradhar R, Wijeysundera DN, Vigod SN. Risk of suicide death following electroconvulsive therapy treatment for depression: a propensity score-weighted, retrospective cohort study in Canada. Lancet Psychiatry. 2022;9:435–46. https://doi.org/10.1016/S2215-0366(22)00077-3 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(22)00077-3</ArticleId><ArticleId IdType="pubmed">35487236</ArticleId></ArticleIdList></Reference><Reference><Citation>Demchenko I, Blumberger DM, Flint AJ, Anderson M, Daskalakis ZJ, Foley K, et al. Electroconvulsive therapy in Canada during the first wave of COVID-19: results of the “What Happened” national survey. J ECT. 2022;38:52–9. https://doi.org/10.1097/YCT.0000000000000801 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/YCT.0000000000000801</ArticleId><ArticleId IdType="pubmed">34519681</ArticleId></ArticleIdList></Reference><Reference><Citation>Robertson J, Flint AJ, Blumberger D, Bhat V. Ethical considerations in providing electroconvulsive therapy during the COVID-19 pandemic. Can J Psychiatry. 2021;66:701–6. https://doi.org/10.1177/0706743721993617 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0706743721993617</ArticleId><ArticleId IdType="pubmed">33596695</ArticleId><ArticleId IdType="pmc">8329900</ArticleId></ArticleIdList></Reference><Reference><Citation>Blumberger DM, Vila-Rodriguez F, Thorpe KE, Feffer K, Noda Y, Giacobbe P, et al. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet. 2018;391:1683–92. https://doi.org/10.1016/S0140-6736(18)30295-2 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)30295-2</ArticleId><ArticleId IdType="pubmed">29726344</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Lazzaro V, Dileone M, Pilato F, Capone F, Musumeci G, Ranieri F, et al. Modulation of motor cortex neuronal networks by rTMS: comparison of local and remote effects of six different protocols of stimulation. J Neurophysiol. 2011;105:2150–6. https://doi.org/10.1152/jn.00781.2010 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/jn.00781.2010</ArticleId><ArticleId IdType="pubmed">21346213</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaster TS, Downar J, Vila-Rodriguez F, Thorpe KE, Feffer K, Noda Y, et al. Trajectories of response to dorsolateral prefrontal rTMS in major depression: a THREE-D study. Am J Psychiatry. 2019;176:367–75. https://doi.org/10.1176/appi.ajp.2018.18091096 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.2018.18091096</ArticleId><ArticleId IdType="pubmed">30764649</ArticleId></ArticleIdList></Reference><Reference><Citation>Trevizol AP, Downar J, Vila-Rodriguez F, Thorpe KE, Daskalakis ZJ, Blumberger DM. Predictors of remission after repetitive transcranial magnetic stimulation for the treatment of major depressive disorder: An analysis from the randomised non-inferiority THREE-D trial. EClinicalMedicine. 2020;22:100349 https://doi.org/10.1016/j.eclinm.2020.100349 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2020.100349</ArticleId><ArticleId IdType="pubmed">32382720</ArticleId><ArticleId IdType="pmc">7200243</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JJ, Zhao LB, Liu YY, Fan SH, Xie P. Comparative efficacy and acceptability of electroconvulsive therapy versus repetitive transcranial magnetic stimulation for major depression: A systematic review and multiple-treatments meta-analysis. Behav Brain Res. 2017;320:30–6. https://doi.org/10.1016/j.bbr.2016.11.028 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2016.11.028</ArticleId><ArticleId IdType="pubmed">27876667</ArticleId></ArticleIdList></Reference><Reference><Citation>Minichino A, Bersani FS, Capra E, Pannese R, Bonanno C, Salviati M, et al. ECT, rTMS, and deepTMS in pharmacoresistant drug-free patients with unipolar depression: a comparative review. Neuropsychiatr Dis Treat. 2012;8:55–64. https://doi.org/10.2147/NDT.S27025 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/NDT.S27025</ArticleId><ArticleId IdType="pubmed">22347797</ArticleId><ArticleId IdType="pmc">3280107</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Klooster DCW, Tik M, Thomas EHX, Downar J, Fitzgerald PB, et al. Accelerated repetitive transcranial magnetic stimulation to treat major depression: the past, present, and future. Harv Rev Psychiatry. 2023;31:142–61. https://doi.org/10.1097/HRP.0000000000000364 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HRP.0000000000000364</ArticleId><ArticleId IdType="pubmed">37171474</ArticleId><ArticleId IdType="pmc">10188211</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams NR, Sudheimer KD, Bentzley BS, Pannu J, Stimpson KH, Duvio D, et al. High-dose spaced theta-burst TMS as a rapid-acting antidepressant in highly refractory depression. Brain. 2018;141:e18 https://doi.org/10.1093/brain/awx379 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx379</ArticleId><ArticleId IdType="pubmed">29415152</ArticleId><ArticleId IdType="pmc">5837258</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole EJ, Phillips AL, Bentzley BS, Stimpson KH, Nejad R, Barmak F, et al. Stanford neuromodulation therapy (SNT): a double-blind randomized controlled trial. Am J Psychiatry. 2022;179:132–41. https://doi.org/10.1176/appi.ajp.2021.20101429 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.2021.20101429</ArticleId><ArticleId IdType="pubmed">34711062</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole EJ, Stimpson KH, Bentzley BS, Gulser M, Cherian K, Tischler C, et al. Stanford accelerated intelligent neuromodulation therapy for treatment-resistant depression. Am J Psychiatry. 2020;177:716–26. https://doi.org/10.1176/appi.ajp.2019.19070720 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.2019.19070720</ArticleId><ArticleId IdType="pubmed">32252538</ArticleId></ArticleIdList></Reference><Reference><Citation>Sackeim HA, Haskett RF, Mulsant BH, Thase ME, Mann JJ, Pettinati HM, et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA. 2001;285:1299–307. https://doi.org/10.1001/jama.285.10.1299 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.285.10.1299</ArticleId><ArticleId IdType="pubmed">11255384</ArticleId></ArticleIdList></Reference><Reference><Citation>Geoly AD, Kratter IH, Toosi P, Cole EJ, Sahlem GL, Williams NR. Sustained efficacy of stanford neuromodulation therapy (SNT) in open-label repeated treatment. Am J Psychiatry. 2024;181:71–3. https://doi.org/10.1176/appi.ajp.20230113 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.20230113</ArticleId><ArticleId IdType="pubmed">38161297</ArticleId></ArticleIdList></Reference><Reference><Citation>Lisanby SH, Sampson S, Husain MM, Petrides G, Knapp RG, McCall WV, et al. Toward individualized post-electroconvulsive therapy care: piloting the Symptom-Titrated, Algorithm-Based Longitudinal ECT (STABLE) intervention. J ECT. 2008;24:179–82. https://doi.org/10.1097/YCT.0b013e318185fa6b .</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/YCT.0b013e318185fa6b</ArticleId><ArticleId IdType="pubmed">18708943</ArticleId><ArticleId IdType="pmc">2743247</ArticleId></ArticleIdList></Reference><Reference><Citation>Lisanby SH, McClintock SM, McCall WV, Knapp RG, Cullum CM, Mueller M, et al. Longitudinal neurocognitive effects of combined electroconvulsive therapy (ECT) and pharmacotherapy in major depressive disorder in older adults: phase 2 of the PRIDE study. Am J Geriatr Psychiatry. 2022;30:15–28. https://doi.org/10.1016/j.jagp.2021.04.006 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jagp.2021.04.006</ArticleId><ArticleId IdType="pubmed">34074611</ArticleId></ArticleIdList></Reference><Reference><Citation>Blumberger DM, Daskalakis ZJ, Vila-Rodriguez F, Boivin-Lafleur D, Goodman MS, Kaster TS, et al. Accelerated intermittent theta burst as a substitute for patients needing electroconvulsive therapy during the COVID-19 pandemic: study protocol for an open-label clinical trial. medRxiv. 2020. https://doi.org/10.1101/2020.12.15.20248260 .</Citation></Reference><Reference><Citation>Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59:22–33.</Citation><ArticleIdList><ArticleId IdType="pubmed">9881538</ArticleId></ArticleIdList></Reference><Reference><Citation>Mir-Moghtadaei A, Caballero R, Fried P, Fox MD, Lee K, Giacobbe P, et al. Concordance between BeamF3 and MRI-neuronavigated target sites for repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex. Brain Stimul. 2015;8:965–73. https://doi.org/10.1016/j.brs.2015.05.008 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brs.2015.05.008</ArticleId><ArticleId IdType="pubmed">26115776</ArticleId><ArticleId IdType="pmc">4833442</ArticleId></ArticleIdList></Reference><Reference><Citation>Konstantinou GN, Downar J, Daskalakis ZJ, Blumberger DM. Accelerated intermittent theta burst stimulation in late-life depression: a possible option for older depressed adults in need of ECT during the COVID-19 pandemic. Am J Geriatr Psychiatry. 2020;28:1025–9. https://doi.org/10.1016/j.jagp.2020.07.007 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jagp.2020.07.007</ArticleId><ArticleId IdType="pubmed">32753340</ArticleId><ArticleId IdType="pmc">7362844</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang YZ, Edwards MJ, Rounis E, Bhatia KP, Rothwell JC. Theta burst stimulation of the human motor cortex. Neuron. 2005;45:201–6. https://doi.org/10.1016/j.neuron.2004.12.033 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2004.12.033</ArticleId><ArticleId IdType="pubmed">15664172</ArticleId></ArticleIdList></Reference><Reference><Citation>Desforges M, Hadas I, Mihov B, Morin Y, Rochette Braun M, Lioumis P, et al. Dose-response of intermittent theta burst stimulation of the prefrontal cortex: A TMS-EEG study. Clin Neurophysiol. 2022;136:158–72. https://doi.org/10.1016/j.clinph.2021.12.018 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2021.12.018</ArticleId><ArticleId IdType="pubmed">35183861</ArticleId></ArticleIdList></Reference><Reference><Citation>Richard M, Noiseux C, Desbeaumes Jodoin V, Blumberger DM, Sheen J, Mansouri F, et al. Prolonged intermittent theta burst stimulation in the treatment of major depressive disorder: a case series. Psychiatry Res. 2022;315:114709 https://doi.org/10.1016/j.psychres.2022.114709 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psychres.2022.114709</ArticleId><ArticleId IdType="pubmed">35816923</ArticleId></ArticleIdList></Reference><Reference><Citation>Li CT, Cheng CM, Lin HC, Yeh SH, Jeng JS, Wu HT, et al. The longer, the better ? Longer left-sided prolonged intermittent theta burst stimulation in patients with major depressive disorder: A randomized sham-controlled study. Asian J Psychiatr. 2023;87:103686 https://doi.org/10.1016/j.ajp.2023.103686 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajp.2023.103686</ArticleId><ArticleId IdType="pubmed">37406605</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamboa OL, Antal A, Moliadze V, Paulus W. Simply longer is not better: reversal of theta burst after-effect with prolonged stimulation. Exp Brain Res. 2010;204:181–7. https://doi.org/10.1007/s00221-010-2293-4 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00221-010-2293-4</ArticleId><ArticleId IdType="pubmed">20567808</ArticleId><ArticleId IdType="pmc">2892066</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramar EA, Babayan AH, Gavin CF, Cox CD, Jafari M, Gall CM, et al. Synaptic evidence for the efficacy of spaced learning. Proc Natl Acad Sci USA. 2012;109:5121–6. https://doi.org/10.1073/pnas.1120700109 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1120700109</ArticleId><ArticleId IdType="pubmed">22411798</ArticleId><ArticleId IdType="pmc">3323981</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch G, Kramar EA, Babayan AH, Rumbaugh G, Gall CM. Differences between synaptic plasticity thresholds result in new timing rules for maximizing long-term potentiation. Neuropharmacology. 2013;64:27–36. https://doi.org/10.1016/j.neuropharm.2012.07.006 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2012.07.006</ArticleId><ArticleId IdType="pubmed">22820276</ArticleId></ArticleIdList></Reference><Reference><Citation>Smolen P, Zhang Y, Byrne JH. The right time to learn: mechanisms and optimization of spaced learning. Nat Rev Neurosci. 2016;17:77–88. https://doi.org/10.1038/nrn.2015.18 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn.2015.18</ArticleId><ArticleId IdType="pubmed">26806627</ArticleId><ArticleId IdType="pmc">5126970</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6:278–96. https://doi.org/10.1111/j.2044-8260.1967.tb00530.x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.2044-8260.1967.tb00530.x</ArticleId><ArticleId IdType="pubmed">6080235</ArticleId></ArticleIdList></Reference><Reference><Citation>Hausmann A, Post T, Post F, Dehning J, Kemmler G, Grunze H. Efficacy of continuation/maintenance electroconvulsive therapy in the treatment of patients with mood disorders: a retrospective analysis. J ECT. 2019;35:122–6. https://doi.org/10.1097/YCT.0000000000000547 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/YCT.0000000000000547</ArticleId><ArticleId IdType="pubmed">30346352</ArticleId></ArticleIdList></Reference><Reference><Citation>Odeberg H, Rodriguez-Silva B, Salander P, Martensson B. Individualized continuation electroconvulsive therapy and medication as a bridge to relapse prevention after an index course of electroconvulsive therapy in severe mood disorders: a naturalistic 3-year cohort study. J ECT. 2008;24:183–90. https://doi.org/10.1097/YCT.0b013e318177275d .</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/YCT.0b013e318177275d</ArticleId><ArticleId IdType="pubmed">18695624</ArticleId></ArticleIdList></Reference><Reference><Citation>Brakemeier EL, Merkl A, Wilbertz G, Quante A, Regen F, Buhrsch N, et al. Cognitive-behavioral therapy as continuation treatment to sustain response after electroconvulsive therapy in depression: a randomized controlled trial. Biol Psychiatry. 2014;76:194–202. https://doi.org/10.1016/j.biopsych.2013.11.030 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2013.11.030</ArticleId><ArticleId IdType="pubmed">24462229</ArticleId></ArticleIdList></Reference><Reference><Citation>Kellner CH, Knapp RG, Petrides G, Rummans TA, Husain MM, Rasmussen K, et al. Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE). Arch Gen Psychiatry. 2006;63:1337–44. https://doi.org/10.1001/archpsyc.63.12.1337 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archpsyc.63.12.1337</ArticleId><ArticleId IdType="pubmed">17146008</ArticleId><ArticleId IdType="pmc">3708140</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck AT, Steer RA, Brown GK Beck Depression Inventory-Second Edition Manual. San Antonio, TX: The Psychological Corporation; 1996.</Citation></Reference><Reference><Citation>Kellner CH, Husain MM, Knapp RG, McCall WV, Petrides G, Rudorfer MV, et al. Right unilateral ultrabrief pulse ECT in geriatric depression: phase 1 of the PRIDE study. Am J Psychiatry. 2016;173:1101–9. https://doi.org/10.1176/appi.ajp.2016.15081101 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.2016.15081101</ArticleId><ArticleId IdType="pubmed">27418379</ArticleId><ArticleId IdType="pmc">7130447</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606–13. https://doi.org/10.1046/j.1525-1497.2001.016009606.x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1525-1497.2001.016009606.x</ArticleId><ArticleId IdType="pubmed">11556941</ArticleId><ArticleId IdType="pmc">1495268</ArticleId></ArticleIdList></Reference><Reference><Citation>Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166:1092–7. https://doi.org/10.1001/archinte.166.10.1092 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.166.10.1092</ArticleId><ArticleId IdType="pubmed">16717171</ArticleId></ArticleIdList></Reference><Reference><Citation>Ustun TB, Chatterji S, Kostanjsek N, Rehm J, Kennedy C, Epping-Jordan J, et al. Developing the World Health Organization Disability Assessment Schedule 2.0. Bull World Health Organ. 2010;88:815–23. https://doi.org/10.2471/BLT.09.067231 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2471/BLT.09.067231</ArticleId><ArticleId IdType="pubmed">21076562</ArticleId><ArticleId IdType="pmc">2971503</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunner DL, Aaronson ST, Sackeim HA, Janicak PG, Carpenter LL, Boyadjis T, et al. A multisite, naturalistic, observational study of transcranial magnetic stimulation for patients with pharmacoresistant major depressive disorder: durability of benefit over a 1-year follow-up period. J Clin Psychiatry. 2014;75:1394–401. https://doi.org/10.4088/JCP.13m08977 .</Citation><ArticleIdList><ArticleId IdType="doi">10.4088/JCP.13m08977</ArticleId><ArticleId IdType="pubmed">25271871</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrens J, Mathews M, Popova V, Borentain S, Rive B, Gonzalez Martin Moro B, et al. Use of Clinical Global Impressions-Severity (CGI-S) to Assess Response to Antidepressant Treatment in Patients with Treatment-Resistant Depression. Neuropsychiatr Dis Treat. 2022;18:1127–32. https://doi.org/10.2147/NDT.S358367 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/NDT.S358367</ArticleId><ArticleId IdType="pubmed">35707064</ArticleId><ArticleId IdType="pmc">9189368</ArticleId></ArticleIdList></Reference><Reference><Citation>Duprat R, Desmyter S, Rudi de R, van Heeringen K, Van den Abbeele D, Tandt H, et al. Accelerated intermittent theta burst stimulation treatment in medication-resistant major depression: A fast road to remission? J Affect Disord. 2016;200:6–14. https://doi.org/10.1016/j.jad.2016.04.015 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2016.04.015</ArticleId><ArticleId IdType="pubmed">27107779</ArticleId></ArticleIdList></Reference><Reference><Citation>McGirr A, Van den Eynde F, Tovar-Perdomo S, Fleck MP, Berlim MT. Effectiveness and acceptability of accelerated repetitive transcranial magnetic stimulation (rTMS) for treatment-resistant major depressive disorder: an open label trial. J Affect Disord. 2015;173:216–20. https://doi.org/10.1016/j.jad.2014.10.068 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2014.10.068</ArticleId><ArticleId IdType="pubmed">25462419</ArticleId></ArticleIdList></Reference><Reference><Citation>Stokes MG, Chambers CD, Gould IC, Henderson TR, Janko NE, Allen NB, et al. Simple metric for scaling motor threshold based on scalp-cortex distance: application to studies using transcranial magnetic stimulation. J Neurophysiol. 2005;94:4520–7. https://doi.org/10.1152/jn.00067.2005 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/jn.00067.2005</ArticleId><ArticleId IdType="pubmed">16135552</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng ZD, Luber B, McClintock SM, Weiner RD, Husain MM, Lisanby SH. Clinical outcomes of magnetic seizure therapy vs electroconvulsive therapy for major depressive episode: a randomized clinical trial. JAMA Psychiatry. 2023. https://doi.org/10.1001/jamapsychiatry.2023.4599 .</Citation></Reference><Reference><Citation>Blumberger DM, Vila-Rodriguez F, Wang W, Knyahnytska Y, Butterfield M, Noda Y, et al. A randomized sham controlled comparison of once vs twice-daily intermittent theta burst stimulation in depression: A Canadian rTMS treatment and biomarker network in depression (CARTBIND) study. Brain Stimul. 2021;14:1447–55. https://doi.org/10.1016/j.brs.2021.09.003 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brs.2021.09.003</ArticleId><ArticleId IdType="pubmed">34560319</ArticleId></ArticleIdList></Reference><Reference><Citation>Pridmore S, May T. Relapse prevention (RP) TMS. Brain Stimul. 2018;11:1391–2. https://doi.org/10.1016/j.brs.2018.08.004 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brs.2018.08.004</ArticleId><ArticleId IdType="pubmed">30143418</ArticleId></ArticleIdList></Reference><Reference><Citation>Rachid F. Maintenance repetitive transcranial magnetic stimulation (rTMS) for relapse prevention in with depression: a review. Psychiatry Res. 2018;262:363–72. https://doi.org/10.1016/j.psychres.2017.09.009 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psychres.2017.09.009</ArticleId><ArticleId IdType="pubmed">28951141</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzgerald PB, Grace N, Hoy KE, Bailey M, Daskalakis ZJ. An open label trial of clustered maintenance rTMS for patients with refractory depression. Brain Stimul. 2013;6:292–7. https://doi.org/10.1016/j.brs.2012.05.003 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brs.2012.05.003</ArticleId><ArticleId IdType="pubmed">22683273</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>